200 Arsenal Yards Boulevard
Suite 230
Watertown, MA 02472
United States
857 285 5300
https://www.kymeratx.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 186
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Dr. Bruce L. Booth DPHIL, Ph.D. | Co-Founder & Independent Chairman | 75k | N/A | 1974 |
Dr. Nello Mainolfi M.D., Ph.D. | Co-Founder, President, CEO & Director | 1.08M | 457.97k | 1979 |
Mr. Bruce N. Jacobs CFA | Chief Financial Officer | 671.2k | 249.77k | N/A |
Dr. Jeremy G. Chadwick Ph.D. | Chief Operating Officer | 883k | N/A | 1963 |
Ms. Ellen V. Chiniara Esq., J.D. | Chief Legal Officer & Corporate Secretary | 640.35k | N/A | 1959 |
Dr. Jared A. Gollob M.D. | Chief Medical Officer | 723.6k | N/A | 1965 |
Ms. Karen Weisbach | Head of People & Culture | N/A | N/A | N/A |
Dr. Juliet Williams B.A Ph.D. | Head of Research | N/A | N/A | N/A |
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Kymera Therapeutics, Inc.’s ISS governance QualityScore as of 1 June 2024 is 7. The pillar scores are Audit: 3; Board: 7; Shareholder rights: 8; Compensation: 8.